I don't know if the comparison is completely valid, but, even when/if functional vaccines are manufactured for COVID-19 if you look to Influenza each year globally there are a great many hospitalisations, and deaths, despite the fairly ready availability of vaccines each year.
It is the treatment of the more severe hospital cases and the possible prevention of death where remestemcel-L might be useful. Not too much time, a matter of months or less will tell for step 1, in the treatment of COVID-19 ARDS.
I'm wondering if the COPD paper will be presented and published as advised now that an ARDS trial is almost here? I hope it will be.
Cell Therapy News/Articles, page-1646
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.210(11.8%) |
Mkt cap ! $1.792B | |||
| Open | High | Low | Value | Volume |
| $1.72 | $1.74 | $1.52 | $15.63M | 9.716M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5127 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 39613 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |